Pfizer to Acquire Excaliard and Sell Lipitor Directly to Patients
Pfizer is to acquire Excaliard, a privately-owned company which creates drugs for the treatment of skin fibrosis, often referred to as skin scarring. As part of the acquisition, Pfizer is obtaining EXC 001, an antisense oligonucleotide currently in Phase II, which is designed to interrupt the process of fibrosis by inhibiting expression of connective tissue